The aim of this study is to evaluate the effects and safety of a dietary supplement, Zataria multiflora Boiss (Shirazi's Thyme) in the treatment of non alcoholic fatty liver disease (NAFLD).
In a randomized double-blind placebo-controlled clinical trial Shirazi's Thyme is compared with placebo. Investigators select randomly 90 patients with NAFLD by inclusion criteria. Investigators measure anthropometric and laboratory parameters including fasting blood sugar, insulin, liver enzymes, lipid profile, and grade in sonography before intervention and 90 days later. Patients are divided into two equal groups. Intervention group in addition to diet and exercise recommendations receive capsules containing 700 mg of Shirazi thyme powder daily for 90 days. Placebo group in addition to the same recommendations for diet and exercise, receives placebo capsules twice daily.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
86
Shahid Motahhari Clinic, Shiraz University of Medical Sciences
Shiraz, Fars, Iran
Change in ALT (Alanin aminotransferase) level
Time frame: 3 months
Change in grade of fatty liver in sonography by use of Saverymuttu Scoring System
Time frame: 3 months
Change in AST (Aspartate aminotransferase) level
Time frame: 3 months
Fasting blood sugar (FBS)
Time frame: 3 months
Change in Gama GT (γ-glutamyl transpeptidase) level
Time frame: 3 monyhs
Fasting insulin level
Time frame: 3 months
Body weight
Time frame: 3 months
Waist circumference
Time frame: 3 months
Hip circumference
Time frame: 3 months
Number of patients with adverse events
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.